Travere Therapeutics
TVTX
121 hedge funds and large institutions have $769M invested in Travere Therapeutics in 2016 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 50 increasing their positions, 41 reducing their positions, and 22 closing their positions.
394% more call options, than puts
Call options by funds: $20.4M | Put options by funds: $4.14M
107.71% more ownership
Funds ownership: 0% → 107.71% (+108%)
22% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 41
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
4% less funds holding
Funds holding: 126 → 121 (-5)
12% less capital invested
Capital invested by funds: $875M → $769M (-$106M)
18% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$17.1M |
| 2 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$13.5M |
| 3 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
+$12.5M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$5.51M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$6.77M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$6.4M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$5.59M |
| 4 |
Morgan Stanley
New York
|
-$5.22M |
| 5 |
IHM
Iguana Healthcare Management
New York
|
-$4.48M |
TVTX Hedge Fund Activity: Q4 2016 in Review
121 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q4 2016, worth a combined $769M — down 12% from $875M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of TVTX and 18 opened new positions — a net loss of 4 holders — while 41 trimmed existing stakes and 50 added.
The largest buyer was Scopia Capital Management, adding an estimated $17.1M. The largest seller was Millennium Management, cutting an estimated $6.77M.
- 121 institutional investors held Travere Therapeutics (TVTX) as of Q4 2016, down from 126 in Q3 2016.
- Funds reported $769M of Travere Therapeutics stock for Q4 2016, down 12% quarter-over-quarter.
- 18 funds opened new Travere Therapeutics positions in Q4 2016 and 22 closed out, a net change of -4 holders.
- The largest Travere Therapeutics buyer in Q4 2016 was Scopia Capital Management, an estimated $17.1M added.
- The largest Travere Therapeutics seller in Q4 2016 was Millennium Management, an estimated $6.77M sold.
Based on aggregated 13F filings for Q4 2016.